A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors

被引：6

作者：

Jhaveri, Komal ^{[1
]}

Juric, Dejan ^{[2
]}

Saura, Cristina ^{[3
]}

Cervantes, Andres ^{[4
]}

Melnyk, Anton ^{[5
]}

Patel, Manish R. ^{[6
]}

Oliveira, Mafalda ^{[3
]}

Gambardella, Valentina ^{[4
]}

Ribrag, Vincent ^{[7
]}

Ma, Cynthia X. ^{[8
]}

Aljumaily, Raid ^{[9
]}

Bedard, Philippe L. ^{[10
]}

Sachdev, Jasgit C. ^{[11
]}

Bond, John ^{[12
]}

Jones, Surai ^{[12
]}

Wilson, Timothy R. ^{[12
]}

Wei, Michael C. ^{[12
]}

Baselga, Jose ^{[1
]}

机构：

[1] Mem Hosp, Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[3] Vall dHebron Univ Hosp, VHIO, Barcelona, Spain

[4] Univ Valencia, Inst Hlth Res INCLIVA, CIBERONC, Valencia, Spain

[5] Texas Oncol Abilene, Abilene, TX USA

[6] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA

[7] Inst Gustave Roussy, Villejuif, France

[8] Washington Univ, Sch Med, St Louis, MO USA

[9] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA

[10] Princess Margaret Canc Ctr, Toronto, ON, Canada

[11] TGen, Honor Hlth Res Inst, Scottsdale, AZ USA

[12] Genentech Inc, San Francisco, CA 94080 USA

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-CT046

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT046

引用

页数：2

共 50 条

[21] SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors [J].

Baselga, J. ;

Cortes, J. ;

De laurentiis, M. ;

Dent, S. ;

Dieras, V. ;

Harbeck, N. ;

Hsu, J. ;

Jin, H. ;

Schimmoller, F. ;

Wilson, T. R. ;

Im, Y-H ;

Jacot, W. ;

Krop, I. E. ;

Verma, S. .

CANCER RESEARCH, 2017, 77

[22] Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer [J].

Saura, Cristina ;

Sachdev, Jasgit ;

Patel, Manish R. ;

Cervantes, Andres ;

Juric, Dejan ;

Infante, Jeffrey R. ;

Richards, Donald ;

Sanabria, Sandra ;

Lu, Xuyang ;

Ware, Joseph ;

Wilson, Timothy R. ;

Parmar, Hema ;

Hsu, Jerry Y. ;

Oliveira, Mafalda ;

Winer, Eric P. ;

Von Hoff, Daniel D. ;

Baselga, Jose ;

Krop, Ian E. .

CANCER RESEARCH, 2015, 75

[23] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors [J].

Juric, Dejan ;

Krop, Ian ;

Ramanathan, Ramesh K. ;

Wilson, Timothy R. ;

Ware, Joseph A. ;

Bohorquez, Sandra M. Sanabria ;

Savage, Heidi M. ;

Sampath, Deepak ;

Salphati, Laurent ;

Lin, Ray S. ;

Jin, Huan ;

Parmar, Hema ;

Hsu, Jerry Y. ;

Von Hoff, Daniel D. ;

Baselga, Jose .

CANCER DISCOVERY, 2017, 7 (07) :704-715

[24] Discovery and development of a new commercial route for a key regulatory starting material in the synthesis of PI3k β-sparing inhibitor GDC-0032 (Taselisib) [J].

Beaudry, Danial R. .

ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248

[25] Neuregulin-1 expression correlates with sensitivity to the PI3K inhibitor, GDC-0032, outside of PIK3CA mutations in head and neck cancer [J].

Savage, Heidi M. ;

O'Brien, Carol ;

Yauch, Bob ;

Settleman, Jeff ;

Lackner, Mark R. ;

Wilson, Timothy R. .

CANCER RESEARCH, 2014, 74 (19)

[26] Expanded biomarker results from a phase I dose escalation study of GDC-0032, a beta isoform-sparing PI3K inhibitor [J].

Wilson, Timothy R. ;

Savage, Heidi ;

O'Brien, Carol ;

Sanabria, Sandra ;

Lin, Ray S. ;

Wagle, Marie-Claire ;

Yan, Yibing ;

Lackner, Mark R. ;

Parmar, Hema ;

Hsu, Jerry Y. ;

Juric, Dejan ;

Krop, Ian E. ;

Ramanathan, Ramesh K. ;

Von Hoff, Daniel D. ;

Baselga, Jose .

CANCER RESEARCH, 2014, 74 (19)

[27] The PI3K inhibitor GDC-0032 enhances the efficacy of standard of care therapeutics in PI3K alpha mutant breast cancer models [J].

Sampath, D. ;

Nannini, M. A. ;

Jane, G. ;

Hong, R. ;

Parsons, K. L. ;

Belvin, M. ;

Friedman, L. S. ;

Wallin, J. J. .

CANCER RESEARCH, 2013, 73

[28] Phase Ia/Ib study of taselisib (GDC-0032), a potent and selective phosphoinositide 3-kinase inhibitor, in Japanese patients with advanced solid tumors or hormone receptor-positive locally advanced or metastatic breast cancer (JO29196 study) [J].

Kobayashi, T. ;

Nakano, K. ;

Tomomatsu, J. ;

Nara, E. ;

Ito, Y. ;

Kobayashi, K. ;

Fukada, I. ;

Araki, K. ;

Shimomura, A. ;

Shimoi, T. ;

Kodaira, M. ;

Yunokawa, M. ;

Yonemori, K. ;

Shimizu, C. ;

Nakamura, K. ;

Kotani, N. ;

Inatani, M. ;

Tamura, K. ;

Takahashi, S. .

CANCER RESEARCH, 2016, 76

[29] A phase Ib study of PI3Kα inhibitor risovalisib mesylate in combination with fulvestrant in patients with PIK3CA-mutated, HR+/HER2-advanced breast cancer [J].

Wu, Jiong ;

Zhang, Jian ;

Li, Man ;

Cai, Li ;

Sun, Tao ;

Ouyang, Quchang ;

Meng, Yanchun ;

Shi, Yehui ;

Wang, Chuan ;

Liu, Qiang ;

Lu, Yongkui ;

Yin, Yongmei ;

Chen, Qianjun ;

Chen, Lilin ;

Wang, Haitao ;

Cui, Jiuwei ;

Liao, Ning ;

Wang, Shubin ;

Tu, Yi ;

Yan, Min .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[30] The P13K inhibitor GDC-0032 is selectively potent against PIK3CA mutant breast cancer cell lines and tumors [J].

Wallin, J. J. ;

Edgar, K. A. ;

Guan, J. ;

Sampath, D. ;

Nannini, M. ;

Belvin, M. ;

Friedman, L. S. .

CANCER RESEARCH, 2013, 73

← 1 2 3 4 5 →